S. 2295 - Patient Safety and Generic Labeling Improvement Act
- Sponsor:
- Patrick J. Leahy
- Summary:
- A bill to permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so. (by CRS)
- Status:
- The bill has been introduced.
Patient Safety and Generic Labeling Improvement Act
S. 2295 — 112th Congress (2011–2012)
- Summary
- A bill to permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so. (by CRS)
- Learn More
- At OpenCongress
- Title
- A bill to permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.
- Other Titles
- Patient Safety and Generic Labeling Improvement Act
- Sponsor
- Patrick J. Leahy
- Co-Sponsors
- Subjects
- Health
- Drug safety, medical device, and laboratory regulation
- Prescription drugs
- Related Bills
- Major Actions
Introduced 4/18/2012 Referred to Committee - Bill History
-
There have been no votes on this bill.
Action Date Description Introduced 4/18/2012 4/18/2012 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. 4/18/2012 Sponsor introductory remarks on measure. Number Sponsor Date Offered Status
Total contributions given to Senators from interest groups that…
supported this bill
opposed this bill
Contributions data source: OpenSecrets.org